Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the present study we analyzed the effect of simultaneous FOXO3 silencing and p27Kip1 activation on breast cancer cell survival and the potential targets of these changes in cancer molecular pathways.
|
31294654 |
2019 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Through pharmacologic approaches, we demonstrated that SRC and PKC negatively regulated expression of the cell-cycle inhibitor protein p27KIP1, and are necessary for CCL2-induced breast cancer cell proliferation.
|
30446625 |
2019 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Tyrosine Phosphorylation of p27Kip1 Correlates with Palbociclib Responsiveness in Breast Cancer Tumor Cells Grown in Explant Culture.
|
30559257 |
2019 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Meanwhile, the up-regulated expression of LAPTM4B together with the down-regulated expression of p27kip1 could classified a group of breast cancer patients with poor prognosis, consequently considered as a potentially prognostic marker and candidate target for therapeutic intervention of triple-negative breast cancer.
|
31033460 |
2019 |
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Landscape of CDKN1B Mutations in Luminal Breast Cancer and Other Hormone-Driven Human Tumors.
|
30065701 |
2018 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, the data reported here demonstrate that miR-24-3p is an important regulator in breast cancer, and imply that the miR-24-3p/p27Kip1 axis has potential as a therapeutic target for breast cancer.
|
26044523 |
2015 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We further propose p27KIP1 expression level may be also a candidate predictive biomarker of rapalogs for breast cancer therapy, which requires additional clinical validation.
|
25744729 |
2015 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the antiproliferative effect of silencing FLOT2 on breast cancer cells was associated with upregulation of cyclin-dependent kinase (CDK) inhibitors p21Cip1 and p27Kip1.
|
25738752 |
2015 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
While in vitro, following release of breast cancer cell lines from serum starvation, the expression of Jab1, phosphor-Akt (p-Akt) was up-regulated, whereas BRSK1 and p27(Kip1) were decreased.
|
25036402 |
2014 |
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Based on this meta-analysis, we conclude that the cyclin-dependent kinase inhibitor 1B rs2066827 polymorphism might not be a risk factor for breast cancer development.
|
24523023 |
2014 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We investigated the effect of the transfected p21 (Waf1) -p27 (Kip1) gene on centrosome duplication, cell proliferation, and apoptosis of MCF-7, a breast cancer cell line.
|
23338153 |
2014 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The mechanism for promoting cell growth is different in each of these cancers and involves a sequence mutation in the pro-molecule facilitating decreased p27(KIP1) levels in CTCL; over expression of the secreted IL-16 molecule to induce proliferation in CTCL T cells, and plasma cells in MM; and increased secreted IL-16 acting to recruit CD4+ pro-tumor macrophages in breast cancer.
|
23893766 |
2014 |
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that breast cancer may be associated with CDKN1B gene rs34330 polymorphism, but not rs2066827 polymorphism.
|
24078094 |
2013 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Among the miRNAs involved in breast cancer, miR-221 plays a crucial role for the following reasons: i) miR-221 is significantly overexpressed in triple-negative primary breast cancer; ii) the oncosuppressor p27Kip1, a validated miR-221 target is downregulated in aggressive cancer cell lines; and iii) the upregulation of a key transcription factor, Slug, appears to be crucial, since it binds to the miR-221/miR-222 promoter and is responsible for the high expression of the miR-221/miR-222 cluster in breast cancer cells.
|
23939688 |
2013 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Stat6 cooperates with Sp1 in controlling breast cancer cell proliferation by modulating the expression of p21(Cip1/WAF1) and p27 (Kip1).
|
23184467 |
2013 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results suggested that Emi1's anti-apoptotic and proliferative abilities appear to be triggered at least in part by the modulation of Skp2, combined Emi1 and Skp2 expressions, may be prognostic for patients with invasive breast carcinomas, which also associated with p-Akt and enabled p27(kip1) degradation.
|
24277465 |
2013 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Peptide nucleic acids targeting miR-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells.
|
22992757 |
2012 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The correlation between nuclear p27(KIP1) expression and estrogen (ER) and progesterone (PR) hormone receptor status was analyzed in 122 human T1N0M0 (68 T1a/b, 54 T1c) breast cancer specimens.
|
22199306 |
2011 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Strikingly, we found that silencing FLOT1 inhibited proliferation and tumorigenicity of breast cancer cells both in vitro and in vivo, which was further shown to be mechanistically associated with suppression of Akt activity, enhanced transcriptional activity of FOXO3a, upregulation of cyclin-dependent kinase inhibitor p21(Cip1) and p27(Kip1), and downregulation of the CDK regulator cyclin D1.
|
21447726 |
2011 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we demonstrated that the anti-proliferative effect of silencing Sam68 on breast cancer cells was associated with up-regulation of cyclin-dependent kinase inhibitor p21(Cip1) and p27(Kip1), enhanced transactivation of FOXO factors, and attenuation of Akt/GSK-3β signalling.
|
20662004 |
2010 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Even though CDKN1B polymorphism appears to be an important predictive factor for breast cancer risk and CCND1 polymorphism may be a prognostic biomarker for breast cancer, further investigations with larger study groups are needed to fully elucidate the role of CCND1 and CDKN1B polymorphisms in the development and prognosis of breast cancer.
|
20683061 |
2010 |
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The 95% confidence intervals for per allele risk estimates excluded a twofold risk, indicating that common CDKN1B polymorphisms do not markedly modify breast cancer risk among BRCA1 or BRCA2 carriers.
|
18543099 |
2009 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Trastuzumab-induced p27(kip1) up-regulation was assessed in a panel of breast cancer cell lines by Western blot analysis.
|
19720293 |
2009 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Over-expression of the ubiquitin ligase Skp2 results in loss of the cell cycle inhibitor p27Kip1 and is associated with poor prognosis in early breast cancer.
|
18644126 |
2008 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Notably, in a primary human breast cancer panel, low p27(kip1) levels inversely correlated with Pin1 expression.
|
18794148 |
2008 |